Celularity Inc. Financing Cash Flow
Celularity Inc. (CELU) reported Financing Cash Flow of $18.65 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-04-30
- Celularity Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $11.22M, a 1644.95% increase year-over-year.
- Celularity Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.48M.
- Celularity Inc. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $1.63M.
- Celularity Inc. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $2.32M, a 62.74% decline year-over-year.
- Celularity Inc. net cash provided by (used in) financing activities for fiscal 2025 was $18.65M, a 178.30% increase from fiscal 2024.
- Celularity Inc. net cash provided by (used in) financing activities for fiscal 2024 was $6.70M, a 72.19% decline from fiscal 2023.
- Celularity Inc. net cash provided by (used in) financing activities for fiscal 2023 was $24.09M, a 79.89% decline from fiscal 2022.
- Celularity Inc. net cash provided by (used in) financing activities for fiscal 2022 was $119.84M, a 21.59% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 1 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 4 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $11.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $14.70M derived: sum of 2 quarters · filed 2026-04-30 | $16.33M derived: sum of 3 quarters · filed 2026-04-30 | $18.65M 10-K · filed 2026-04-30 | ||||
| 2025-09-30 | $3.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.11M derived: sum of 2 quarters · filed 2025-11-14 | $7.43M 10-Q · filed 2025-11-14 | $8.07M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2025-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $3.95M 10-Q · filed 2025-08-29 | $4.59M derived: sum of 3 quarters · filed 2026-04-30 | $4.51M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2025-03-31 | $2.32M 10-Q · filed 2025-08-29 | $2.96M derived: sum of 2 quarters · filed 2026-04-30 | $2.88M derived: sum of 3 quarters · filed 2026-04-30 | $2.79M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $643.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $564.00K derived: sum of 2 quarters · filed 2026-04-30 | $474.00K derived: sum of 3 quarters · filed 2026-04-30 | $6.70M 10-K · filed 2026-04-30 | ||||
| 2024-09-30 | -$79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$169.00K derived: sum of 2 quarters · filed 2025-11-14 | $6.06M 10-Q · filed 2025-11-14 | $6.04M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | -$90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $6.14M 10-Q · filed 2025-08-29 | $6.12M derived: sum of 3 quarters · filed 2025-08-29 | $11.86M derived: sum of 4 quarters · filed 2025-08-29 | ||||
| 2024-03-31 | $6.23M 10-Q · filed 2025-08-29 | $6.21M derived: sum of 2 quarters · filed 2025-08-29 | $11.95M derived: sum of 3 quarters · filed 2025-08-29 | $17.56M derived: sum of 4 quarters · filed 2025-08-29 | ||||
| 2023-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $5.72M derived: sum of 2 quarters · filed 2025-05-08 | $11.34M derived: sum of 3 quarters · filed 2025-05-08 | $24.09M 10-K · filed 2025-05-08 | ||||
| 2023-09-30 | $5.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $11.35M derived: sum of 2 quarters · filed 2024-12-06 | $24.11M 10-Q · filed 2024-12-06 | $25.79M derived: sum of 4 quarters · filed 2024-12-06 | ||||
| 2023-06-30 | $5.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $18.37M 10-Q · filed 2024-11-07 | $20.05M derived: sum of 3 quarters · filed 2024-11-07 | $63.99M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-03-31 | $12.76M 10-Q · filed 2024-10-16 | $14.44M derived: sum of 2 quarters · filed 2024-10-16 | $58.38M derived: sum of 3 quarters · filed 2024-10-16 | $86.10M derived: sum of 4 quarters · filed 2024-10-16 | ||||
| 2022-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $45.62M derived: sum of 2 quarters · filed 2024-07-30 | $73.34M derived: sum of 3 quarters · filed 2024-07-30 | $119.84M 10-K · filed 2024-07-30 | ||||
| 2022-09-30 | $43.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $71.66M derived: sum of 2 quarters · filed 2024-01-03 | $118.15M 10-Q · filed 2024-01-03 | $117.14M derived: sum of 4 quarters · filed 2024-01-03 | ||||
| 2022-06-30 | $27.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $74.21M 10-Q · filed 2023-08-14 | $73.20M derived: sum of 3 quarters · filed 2023-08-14 | $173.60M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $46.49M 10-Q · filed 2023-05-22 | $45.48M derived: sum of 2 quarters · filed 2023-05-22 | $145.88M derived: sum of 3 quarters · filed 2023-05-22 | $149.90M derived: sum of 4 quarters · filed 2023-05-22 | ||||
| 2021-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $99.39M derived: sum of 2 quarters · filed 2023-03-31 | $103.40M derived: sum of 3 quarters · filed 2023-03-31 | $98.56M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $100.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $104.42M derived: sum of 2 quarters · filed 2022-11-10 | $99.58M 10-Q · filed 2022-11-10 | $99.26M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $4.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$827.00K 10-Q · filed 2022-08-09 | $1.11M 10-Q · filed 2021-08-19 | -$1.14M derived: sum of 3 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$4.84M 10-Q · filed 2022-05-16 | $120.00K 10-Q · filed 2021-05-24 | -$5.16M derived: sum of 2 quarters · filed 2022-05-16 | |||||
| 2020-12-31 | -$317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $102.01M 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | $102.33M 10-Q · filed 2021-11-12 | |||||||
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-24 | $0.00 derived: sum of 2 quarters · filed 2021-05-24 | $288.84M derived: sum of 3 quarters · filed 2021-05-24 | $288.84M 10-K/A · filed 2021-05-24 | ||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $288.84M derived: sum of 2 quarters · filed 2020-11-16 | $288.84M 10-Q · filed 2020-11-16 | |||||
| 2019-06-30 | $288.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $288.84M 10-Q · filed 2020-08-13 | ||||||
| 2019-03-31 | -$5.15K 10-Q · filed 2020-05-15 | |||||||
| 2018-12-31 | $25.25K 10-K · filed 2020-03-24 | |||||||
| 2018-09-30 | $10.00K 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |